Cosmo Pharmaceuticals N.V. reiterated earnings guidance for the Year 2023 . For the year, company expects total revenue between EUR 110 million and EUR 120 million, operating profit between EUR 25 million and EUR 35 million.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
71.3 CHF | +0.42% | +1.57% | +40.08% |
Jun. 18 | Switzerland's Cosmo Pharmaceuticals Receives Drug Registration Certificate for Lumeblue in China | MT |
Jun. 03 | Cosmo Pharmaceuticals Swings to Loss in FY23; Revenue Down | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+40.08% | 1.27B | |
+54.07% | 809B | |
+38.95% | 621B | |
-7.05% | 351B | |
+15.44% | 319B | |
+5.72% | 289B | |
+14.21% | 238B | |
-0.45% | 221B | |
+14.58% | 218B | |
+7.42% | 166B |
- Stock Market
- Equities
- COPN Stock
- News Cosmo Pharmaceuticals N.V.
- Cosmo Pharmaceuticals N.V. Reiterates Earnings Guidance for the Year 2023